Pricing

Tango Therapeutics Inc (TNGX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Barbara L. Weber
Employees:
90
201 BROOKLINE AVENUE, SUITE 901, BOSTON, MA, 02215
(857) 320-4900
Tango Therapeutics, Inc. discovers and develops drugs for the treatment of cancer. Lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. Company also develops Ubiquitin-specific protease 1 and Target 3 for STK11-mutant cancers.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available